[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100399703":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":61,"collaborators":38,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":38,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":38,"enrollmentInfo":73,"targetDuration":38,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":38,"overallStatus":46,"whyStopped":38,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Zagazig University","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group IH(inhaled milrinone)","ACTIVE_COMPARATOR","After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg\u002Fml) is initiated and intravenous placebo ( normal saline )infusion are administered",[13],"Drug: Milrinone inhalation",{"label":15,"type":10,"description":16,"interventionNames":17},"Group Iv(Intravenous milrinone)","After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg\u002Fml) (0.5 μg\u002Fkg\u002Fmin)infusion are administered",[18],"Drug: Milrinone infusion",[20,26],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Milrinone inhalation",[9],[25],"primacor",{"type":21,"name":27,"description":16,"armGroupLabels":28,"otherNames":29},"Milrinone infusion",[15],[25],[31],{"name":32,"affiliation":5,"role":33},"Heba M EL-Asser, MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":32,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","01062393152",null,"aseelaswad1@yahoo.com",{"name":41,"role":36,"phone":42,"phoneExt":38,"email":43},"Amany S abdelazeem, MD","01287220016","dola.salah2009@gmail.com",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Zagazig","Sharqia Province","44519","Egypt","EG",{"type":53,"coordinates":54},"Point",[55,56],31.502,30.58768,{"lat":56,"lon":55},[59],{"name":60,"role":36,"phone":37,"phoneExt":38,"email":39},"Heba M Elasser, MD",{"type":33,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Heba Mohamed EL -Asser,MD","principal investigator","100399703","phase-4-inhaled-and-intravenous-milrinone-in-patients-with-severe-pulmonary-hypertension-100399703",false,"NCT04484675","Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension","Comparative Study Between Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Patients scheduled to undergo mitral valve surgery by cardiopulmonary bypass with estimated mean pulmonary artery pressure =\\>55 estimated by using preoperative Doppler echocardiography\n\nExclusion Criteria:\n\nPatients were excluded if they had surgery without CPB, preoperative hemodynamic instability (defined as acute requirement for vasoactive support or mechanical device),Patients with severe LV dysfunction (LV ejection fraction of less than 30% congenital heart disease, a contraindication to transesophageal echocardiography (TEE), emergency surgery or re-do surgeries severe renal or hepatic disease\n\n, coagulopathy, and thromboembolic disease treated with anticoagulants","ALL","18 Years",{"count":74,"type":75},38,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery",[81],"Pulmonary Hypertension Due to Left Heart Disease","2025-04-26",{"date":84,"type":85},"2025-04-30","ACTUAL",{"date":87,"type":85},"2023-05-20",{"date":89,"type":75},"2025-05-10",{"name":5,"class":6},1]